IDO1 and acute myeloid leukemia: In addition, administration of anti-CD33/CD3 antibody (AMG 330) triggered T cell-mediated lysis of AML blasts that was further enhanced by T cell elimination of IDO+CD33+ MDSCs (IDO, an enzyme released by cancer cells to deplete tryptophan leading to suppressed T cell activities) (115).